RDUS实时信号 | 通过Getagraph.com最大化利润

出售 110603 min ago

@ $24.14

发出时间: 15 Feb 2024 @ 01:18

回报率: -27.84%

上一信号: Feb 13 - 04:20

上一信号: 购买

回报率: -4.60 %

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 04:00):

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...

Stats
今日成交量	283 615
平均成交量	248 839
市值	489.75M
EPS	$0 ( 2024-04-03 )
Last Dividend	$0.188 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	-11.34
ATR14	$0.0280 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Kelley Erika K.	Buy	0
2024-02-20	Minor Glenda J	Buy	95	Class A Common Stock
2024-02-20	Sutherlin Michael W	Buy	406	Class A Common Stock
2024-02-20	Shoemaker Leslie L	Buy	43	Class A Common Stock
2024-02-20	Jahnke David L	Buy	515	Class A Common Stock

INSIDER POWER
-79.24
Last 94 transactions
Buy: 7 552 389 \| Sell: 18 343 130

音量相关性

長: -0.07 (neutral)

短: -0.24 (neutral)

Signal:(42.91) Neutral

Radius Health Inc 相关性

10 最正相关
COUP	0.943
APR	0.931
ICON	0.929
FTDR	0.921
ASTL	0.92
DFH	0.918
CRVL	0.917
KIN	0.915
CLBT	0.904
RMRM	0.902

10 最负相关
ORRF	-0.913
SABS	-0.913
MMAC	-0.908
LUCD	-0.908
VIEW	-0.905
AMRB	-0.89
SGMA	-0.887
LCAP	-0.885
LGHL	-0.884
TRIT	-0.883

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Radius Health Inc 相关性 - 货币/商品

-0.03
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.10
( neutral )

Radius Health Inc 财务报表

Annual	2023
营收:	$2.88B
毛利润:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2023
营收:	$2.88B
毛利润:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2022
营收:	$3.49B
毛利润:	$488.07M (14.00 %)
EPS:	$6.01

FY	2021
营收:	$229.97M
毛利润:	$210.82M (91.67 %)
EPS:	$-1.484

Financial Reports:

No articles found.

Radius Health Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Radius Health Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.22 - good (82.18%) | Divividend Growth Potential Score: 5.28 - Stable (5.50%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.188	2023-04-21
Last Dividend	$0.188	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-11-27
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.563	--
Avg. Dividend % Per Year	0.60%	--
Score	3.79	--
Div. Sustainability Score	8.22
Div.Growth Potential Score	5.28
Div. Directional Score	6.75	--

Next Divdend (Est)
(2024-07-01)

$0.188 Estimate 22.50 %

Dividend Stability

0.60 Above Average

Dividend Score

3.79

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2023	$0.564	1.80%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00339	1.500	9.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00556	1.200	9.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.0111	1.500	-0.988	-1.482	[0.1 - 1]
payoutRatioTTM	2.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.927	0.800	5.36	4.29	[1 - 3]
quickRatioTTM	0.883	0.800	9.51	7.61	[0.8 - 2.5]
cashRatioTTM	0.0132	1.500	-1.038	-1.557	[0.2 - 2]
debtRatioTTM	0.251	-1.500	5.81	-8.71	[0 - 0.6]
interestCoverageTTM	2.18	1.000	-0.303	-0.303	[3 - 30]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.095	2.00	9.45	10.00	[0 - 20]
debtEquityRatioTTM	0.501	-1.500	7.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0989	1.000	-1.685	-1.685	[0.2 - 0.8]
operatingProfitMarginTTM	0.0117	1.000	-1.766	-1.766	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.392	1.000	8.93	8.93	[0.2 - 2]
assetTurnoverTTM	1.639	0.800	2.41	1.926	[0.5 - 2]
Total Score				8.22

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.20	1.000	5.33	0	[1 - 100]
returnOnEquityTTM	0.0111	2.50	-0.635	-1.482	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.095	2.00	9.64	10.00	[0 - 30]
dividendYielPercentageTTM	4.31	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
payoutRatioTTM	2.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.850	1.500	7.67	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0602	1.000	-0.994	0	[0.1 - 0.5]
Total Score				5.28

Radius Health Inc

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.